Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
158.71
+0.81 (+0.51%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
48
49
Next >
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi
July 10, 2023
Biogen's shares decline after approval of Alzheimer's treatment Leqembi, which modestly slows cognitive decline. Analysts see hurdles to the rollout.
Via
MarketBeat
Exposures
Product Safety
Biogen Just Reached a Big Milestone. Why Isn't the Stock Rising?
July 09, 2023
Biogen shares are little changed year to date.
Via
The Motley Fool
Mixed Jobs Data; Fed Governors Want More Interest Rate Hikes; US, China Spat Rattles Semiconductor Sector: The Week In The Markets
July 07, 2023
Via
Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $4,900 Today
July 07, 2023
Via
Benzinga
Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts
July 07, 2023
The FDA approved a supplemental marketing application for Biogen Inc (NASDAQ: BIIB)-Eisai Co Ltd (OTC: ESALY) supporting the traditional approval of Leqembi (lecanemab-irmb), making it the first and...
Via
Benzinga
What 29 Analyst Ratings Have To Say About Biogen
July 07, 2023
Via
Benzinga
What's Going On With Biogen Stock Thursday
July 06, 2023
Biogen Inc (NASDAQ: BIIB) shares were flat in Thursday's after-hours session after falling marginally by 0.31% to $284.99 during
Via
Benzinga
FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline
July 07, 2023
The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval.
Via
Benzinga
Stock Market Rally Pulls Back As Yields Jump; Tesla, Meta In Focus: Weekly Review
July 07, 2023
Automakers rallied on sales while Meta's Threads had a big launch.
Via
Investor's Business Daily
FSLR Stock Alert: The $1 Billion Reason First Solar Is Up Today
July 07, 2023
First Solar (FSLR) stock is rising higher on Friday after the solar energy company announced a $1 billion revolving credit facility.
Via
InvestorPlace
Why Is Alibaba (BABA) Stock Up Today?
July 07, 2023
Alibaba (BABA) stock is on the rise Friday as investors react to a few pieces of news considering the Chinese e-commerce giant.
Via
InvestorPlace
BIIB Stock Alert: What to Know as FDA Approves Biogen’s Alzheimer’s Drug
July 07, 2023
Biogen (BIIB) stock is in the news Friday after the pharmaceutical company got approval from the FDA for its Alzheimer's drug.
Via
InvestorPlace
How Is The Market Feeling About Biogen?
June 29, 2023
Via
Benzinga
A Look Into Biogen Inc's Price Over Earnings
June 27, 2023
Via
Benzinga
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
June 21, 2023
Via
Benzinga
Stock Futures Dip As Traders Eye Friday Jobs Report: Analyst Says Q3 Returns Hinge More On This Catalyst Than Fed Move
July 07, 2023
Via
Benzinga
Top 5 Trending Stocks: Prestige Wealth's IPO, Rivian's Lawsuit, Meta's New Platform, Tesla's Dip, And Biogen's FDA Approval
July 06, 2023
Via
Benzinga
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
July 06, 2023
From
Biogen Inc.
Via
GlobeNewswire
3 Biotech Stocks to Make Your ‘Get Rich’ Dreams Come True
July 06, 2023
These high return biotech stocks offer tremendous upside ahead and are likely to soar on the back of several growth drivers
Via
InvestorPlace
Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment
July 06, 2023
The FDA is expected to announce Thursday whether it has approved or rejected Biogen's Alzheimer's drug.
Via
Investor's Business Daily
Does This Signal Trouble for Biogen's New Alzheimer's Drug?
June 19, 2023
Biogen is counting on Leqembi to boost its revenue growth.
Via
The Motley Fool
Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment
July 03, 2023
Biogen Inc (NASDAQ: BIIB) announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting
Via
Benzinga
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
June 30, 2023
From
Biogen Inc.
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
June 30, 2023
Via
Benzinga
Amgen Inc. Dividend Stock Analysis
June 30, 2023
The company has paid a cash dividend to shareholders every year since 2011 and has increased its dividend payments for 13 consecutive years.
Via
Talk Markets
Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?
June 23, 2023
The catalyst many Biogen investors have been waiting for may soon arrive.
Via
The Motley Fool
Alleged Industrial Espionage Makes an Interesting Story
June 21, 2023
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.
Via
The Motley Fool
5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies
June 20, 2023
Via
Benzinga
How to Retire Rich: Biotech Stocks Edition
June 18, 2023
Thanks to its enormous and practically permanent relevancies, the biotech sector offers a great avenue for retirement planning stocks.
Via
InvestorPlace
2 Market-Beating Stocks With Major Catalysts on the Way
June 17, 2023
Can these companies keep climbing?
Via
The Motley Fool
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
48
49
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.